Dec 10, 2021 08:59 PM (GMT+8) · EqualOcean
On December 9, Beijing Anshi Biotechnology Co., Ltd. (hereinafter referred to as "Anshi biotechnology"), which focuses on the research and development of a new generation of targeted drugs for precision therapy, announced that it had completed a round of financing of more than US $200 million. This round of investment was led by vivo capital and deeply participated by Bain Capital, Chunhua capital and other funds. At the same time of the transaction, the company completed the acquisition of another clinical biotechnology company, Beijing purun'ao Biotechnology Co., Ltd. (hereinafter referred to as "purun'ao biology"), and created a R & D platform with a variety of new generation targeted drugs for precision treatment. This round of financing will help Anshi biology complete the acquisition of purun'ao biology, accelerate the promotion of candidate drugs, the expansion of product lines and support the clinical development and commercialization preparation of the company's core products, so as to provide more effective and safe treatment options for patients in China and around the world. It is reported that the candidate drugs of Anshi biological c-met target are in the late stage of clinical development and have been recognized as breakthrough therapies issued by the China food and Drug Administration this year. The wide product pipeline of Anshi biology includes a class of innovative drug candidates in phase I clinical research and multiple self-developed candidate compounds in preclinical and ind stages.

This text is a result of machine translation.